Krystal Biotech, Inc. (NASDAQ:KRYS) Sees Significant Decrease in Short Interest

Krystal Biotech, Inc. (NASDAQ:KRYS) was the recipient of a significant decline in short interest in January. As of January 31st, there was short interest totalling 3,010,000 shares, a decline of 7.4% from the January 15th total of 3,250,000 shares. Based on an average trading volume of 262,600 shares, the short-interest ratio is currently 11.5 days.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

A number of large investors have recently made changes to their positions in the company. Norges Bank acquired a new position in shares of Krystal Biotech during the 4th quarter worth approximately $34,391,000. Soleus Capital Management L.P. grew its position in Krystal Biotech by 65.2% during the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock worth $56,144,000 after buying an additional 141,400 shares in the last quarter. Segall Bryant & Hamill LLC increased its stake in Krystal Biotech by 352.4% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock worth $28,605,000 after acquiring an additional 122,407 shares during the period. State Street Corp raised its holdings in Krystal Biotech by 9.0% in the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after acquiring an additional 119,936 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Krystal Biotech in the 4th quarter valued at $15,989,000. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $156.69 on Wednesday. Krystal Biotech has a 52 week low of $107.50 and a 52 week high of $219.34. The stock has a market capitalization of $4.51 billion, a P/E ratio of 88.53 and a beta of 0.84. The stock has a 50-day simple moving average of $157.98 and a 200 day simple moving average of $175.42.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a report on Wednesday, December 18th. Chardan Capital reissued a “buy” rating and issued a $212.00 price target on shares of Krystal Biotech in a research note on Wednesday, December 18th. Finally, Citigroup lifted their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $206.67.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).